Core Viewpoint - Meihua Medical (301363) reported a slight decline in stock price and mixed financial results for Q3 2025, indicating growth in revenue but a significant drop in net profit year-to-date. Financial Performance - For Q3 2025, the company achieved operating revenue of 461,657,375.39 yuan, a year-on-year increase of 2.56% [1] - Year-to-date operating revenue reached 1,194,474,058.15 yuan, reflecting a growth of 3.28% compared to the same period last year [1] - The net profit attributable to shareholders for Q3 was 93,900,188.71 yuan, up 5.89% year-on-year, but down 19.25% year-to-date at 208,202,331.16 yuan [1][2] - The net profit excluding non-recurring gains and losses for Q3 was 92,706,846.77 yuan, a 9.56% increase year-on-year, while year-to-date it was 203,344,046.58 yuan, down 17.85% [1][2] Cash Flow and Earnings - The net cash flow from operating activities year-to-date was 221,973,418.65 yuan, a decrease of 26.43% compared to the previous year [2] - Basic earnings per share for Q3 were 0.17 yuan, a 13.33% increase year-on-year, but year-to-date it was 0.37 yuan, down 17.78% [2] - The weighted average return on equity year-to-date was 5.79%, a decline of 2.07 percentage points from the previous year [2] Asset and Equity Position - As of the end of the reporting period, total assets amounted to 4,179,497,349.18 yuan, an increase of 6.58% from the previous year-end [2] - The equity attributable to shareholders was 3,701,969,775.59 yuan, up 6.39% from the previous year-end [2] - The total number of common shareholders at the end of the reporting period was 14,389 [2]

Core Viewpoint - The company announced the convening of its second board meeting on October 21, 2025, to review the profit distribution plan for the first three quarters of 2025, which will be submitted for approval at the third extraordinary shareholders' meeting of 2025 [1] Group 1 - The second board meeting is scheduled for October 21, 2025 [1] - The agenda includes the review of the profit distribution proposal for the first three quarters of 2025 [1] - The proposal requires approval from the third extraordinary shareholders' meeting of 2025 [1]

Core Insights - The company reported a revenue of 461,657,375.39 yuan for the third quarter of 2025, representing a year-on-year growth of 2.56% [2] - The net profit attributable to shareholders of the listed company was 93,900,188.71 yuan, showing a year-on-year increase of 5.89% [2] Financial Performance - Revenue for Q3 2025: 461.66 million yuan, up 2.56% year-on-year [2] - Net profit for Q3 2025: 93.90 million yuan, up 5.89% year-on-year [2]

Core Viewpoint - Meihua Medical reported a significant enhancement in profitability for the third quarter of 2025, with a year-on-year revenue increase and a proposed cash dividend distribution to shareholders [1] Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 1.194 billion yuan, representing a year-on-year growth of 3.28% [1] - The net profit for the same period was 208 million yuan [1] - In the third quarter alone, revenue reached 462 million yuan, marking a year-on-year increase of 2.56% [1] - The net profit for the third quarter was 93.9 million yuan, reflecting a year-on-year growth of 5.89% [1] Profit Distribution Plan - The company announced a profit distribution plan based on a total share capital of 569 million shares, proposing a cash dividend of 0.80 yuan for every 10 shares, totaling 45.42 million yuan (including tax) [1] - This distribution is aligned with the company's development stage and profitability, aiming to share operational results with shareholders [1] Business Strategy - Meihua Medical focuses on the design, manufacturing, and sales of precision components and products in the medical device sector, providing a comprehensive one-stop service [1] - The company aims to become a leading global medical technology service provider [1] - The growth in the medical device and CDMO industry is seen as a favorable external condition for business expansion [1] - A diversified business layout is identified as a long-term growth driver [1] - The company plans to expand its market focus on leading medical device enterprises in Europe and the United States, as well as localizing operations in China [1] - Collaborations with domestic and innovative high-tech medical enterprises are also highlighted as key future business priorities [1]

证券之星消息，截至2025年10月21日收盘，美好医疗(301363)报收于22.37元，下跌0.18%，换手率 0.93%，成交量3.47万手，成交额7782.55万元。 10月21日的资金流向数据方面，主力资金净流出610.11万元，占总成交额7.84%，游资资金净流出232.7 万元，占总成交额2.99%，散户资金净流入842.81万元，占总成交额10.83%。 近5日资金流向一览见下表： 该股最近90天内共有17家机构给出评级，买入评级15家，增持评级2家；过去90天内机构目标均价为 24.42。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | -- ...

Core Insights - The company reported a revenue of 1.194 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 3.28% [1] - The net profit attributable to shareholders for the same period was 208 million yuan, showing a year-on-year decline of 19.25% [1] - The company announced a profit distribution plan, proposing a cash dividend of 0.8 yuan (including tax) per 10 shares to all shareholders [1]

Group 1 - Pinggao Electric reported a 6.98% increase in revenue to 8.436 billion yuan and a 14.62% increase in net profit to 982 million yuan for the first three quarters of 2025 [1] - Wanchen Group achieved a 77.37% increase in revenue to 36.562 billion yuan and a staggering 917.04% increase in net profit to 855 million yuan for the first three quarters of 2025 [2] - Xintian's revenue decreased by 10.42% to 481 million yuan, with a net profit decline of 35.19% to 91.9 million yuan for the first three quarters of 2025 [3] Group 2 - Chuangye Heima reported a revenue drop of 35.68% to 102 million yuan and a net loss of 24.93 million yuan for the first three quarters of 2025 [4] - Huaxin New Materials saw a 16.11% increase in revenue to 265 million yuan and an 18.56% increase in net profit to 40.81 million yuan for the first three quarters of 2025 [5] - Meihua Medical's revenue increased by 3.28% to 1.194 billion yuan, but net profit fell by 19.25% to 208 million yuan for the first three quarters of 2025 [6] Group 3 - Silica Technology reported a 24.30% increase in revenue to 2.651 billion yuan and a 44.63% increase in net profit to 229 million yuan for the first three quarters of 2025 [7] - Anada experienced a revenue decline of 6.03% to 1.31 billion yuan and a net loss of 46.37 million yuan for the first three quarters of 2025 [8] - StarNet Ruijie achieved a 19.20% increase in revenue to 14.168 billion yuan and a 31.06% increase in net profit to 344 million yuan for the first three quarters of 2025 [9] Group 4 - New Link Electronics reported a revenue decrease of 0.37% to 550 million yuan but a significant net profit increase of 421.43% to 535 million yuan for the first three quarters of 2025 [10] - Tianyin Electromechanical's revenue fell by 22.75% to 581 million yuan, with a net profit decline of 56.10% to 24.27 million yuan for the first three quarters of 2025 [11] - Hengtong Co. reported a revenue decrease of 39.29% to 1.05 billion yuan, but a net profit increase of 78.33% to 176 million yuan for the first three quarters of 2025 [12] Group 5 - Xigao Institute achieved a 15.05% revenue increase to 651 million yuan and a 21.28% net profit increase to 198 million yuan for the first three quarters of 2025 [13] - Good Housewife reported a revenue decrease of 0.91% to 1.059 billion yuan and a net profit decline of 24.79% to 143 million yuan for the first three quarters of 2025 [14] - China Pharmaceutical's subsidiary received approval for Vitamin B6 injection, indicating a positive development in its product pipeline [20] Group 6 - Xi Zhong Technology received approval for the issuance of convertible bonds, indicating potential for future capital raising [22] - Chengda Bio signed a strategic cooperation agreement with the Chinese Academy of Microbiology, focusing on infectious disease prevention [25] - Fuyuan Pharmaceutical received a drug registration certificate for Dydrogesterone tablets, enhancing its product offerings [26] Group 7 - Zhehai Deman received 8.1202 million yuan in land acquisition compensation, indicating a successful resolution of land-related issues [27] - Zhongjin Irradiation announced the resignation of its deputy general manager, indicating potential changes in management [29] - Hendi Pharmaceutical received a drug registration certificate for Febuxostat tablets, expanding its product portfolio [30] Group 8 - David Medical's subsidiary received a medical device registration certificate for a surgical stapler, enhancing its product offerings [32] - Liaoning Energy announced plans for a share reduction by a major shareholder, indicating potential changes in ownership structure [34] - Fengyuan Co. signed a framework agreement for the supply of lithium iron phosphate, indicating growth in its supply chain [35] Group 9 - Shengda Resources announced the resumption of construction at a mining site, indicating recovery from previous operational disruptions [37] - Shiyuan Co. reported a revenue increase of 5.45% to 18.087 billion yuan, but a net profit decline of 6.81% to 867 million yuan for the first three quarters of 2025 [39] - Feilida reported a revenue decrease of 6.81% to 4.659 billion yuan, but a net profit increase of 49.1% to 33.19 million yuan for the first three quarters of 2025 [40] Group 10 - Changyuan Donggu reported a revenue increase of 29.75% to 1.648 billion yuan and a net profit increase of 76.71% to 274 million yuan for the first three quarters of 2025 [41] - Liyuanheng reported a net profit of 47.49 million yuan for the first three quarters of 2025, indicating stable performance [42] - Fangyuan Co. reported a net loss of 121 million yuan for the first three quarters of 2025, indicating challenges in its operations [43] Group 11 - China Mobile reported a revenue increase of 0.4% to 794.7 billion yuan and a net profit increase of 4% to 115.4 billion yuan for the first three quarters of 2025 [44] - Huangshanghuang reported a revenue decrease of 5.08% to 1.379 billion yuan but a net profit increase of 28.59% to 101 million yuan for the first three quarters of 2025 [46] - Youcai Resources announced plans to invest approximately 150 million yuan in a new materials production base project [47] Group 12 - Huawei Technology announced plans to invest up to 20 million euros in two German subsidiaries [49] - China Shipbuilding projected a net profit increase of 144.42% to 170.85% for the first three quarters of 2025, indicating strong performance [51] - Aeston's subsidiary plans to transfer a 48% stake in a company for 245 million yuan, indicating strategic divestment [52] Group 13 - Jinxinno plans to raise up to 292 million yuan through a private placement, indicating potential for expansion [53] - China Power Construction reported a 5.04% increase in new contract amounts to 904.527 billion yuan for the first three quarters of 2025 [54] - Helitai reported a net profit increase of 101.45% to 17.81 million yuan for the first three quarters of 2025 [55] Group 14 - Xuefeng Technology reported a revenue decrease of 8.28% to 4.183 billion yuan and a net profit decline of 34.6% to 394 million yuan for the first three quarters of 2025 [57] - Juzhi Technology reported a revenue increase of 21.40% to 615 million yuan and a net profit increase of 33.78% to 82.47 million yuan for the first three quarters of 2025 [59] - Jinxi Axle reported a revenue decrease of 0.11% to 872 million yuan but a net profit increase of 268.03% to 22.11 million yuan for the first three quarters of 2025 [60] Group 15 - Longsheng Technology reported a revenue increase of 10.13% to 1.810 billion yuan and a net profit increase of 36.89% to 210 million yuan for the first three quarters of 2025 [62] - Shannon Chip Creation announced plans for a share reduction by a major shareholder, indicating potential changes in ownership structure [63]

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经头条（nbdtoutiao）——展望"十五五"|专访贺铿：必须改变以往将资金过度集中于房屋建设和基础 设施建设的倾向，更加突出民生领域投入 （记者 王瀚黎） 每经AI快讯，美好医疗10月21日晚间发布三季度业绩公告称，2025年前三季度营收约11.94亿元，同比 增加3.28%；归属于上市公司股东的净利润约2.08亿元，同比减少19.25%；基本每股收益0.37元，同比 减少17.78%。 ...

美好医疗(301363.SZ)披露2025年三季度报告，公司第三季度实现营业收入4.62亿元，同比增长2.56%； 归母净利润9390.02万元，同比增长5.89%。前三季度实现营业收入11.94亿元，同比增长3.28%；归母净 利润2.08亿元，同比下降19.25%。公司拟每10股派发现金红利0.8元（含税）。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

格隆汇10月21日丨美好医疗(301363.SZ)公布三季度报告，前三季营业收入11.94亿元，同比增长3.28%， 归属于上市公司股东的净利润2.08亿元，同比下降19.25%，归属于上市公司股东的扣除非经常性损益的 净利润2.03亿元，同比下降17.85%。 ...